Assenagon Asset Management S.A. Decreases Stake in Evolus, Inc. $EOLS

Assenagon Asset Management S.A. cut its stake in Evolus, Inc. (NASDAQ:EOLS) by 53.3% in the third quarter, Holdings Channel reports. The firm owned 285,782 shares of the company’s stock after selling 326,606 shares during the period. Assenagon Asset Management S.A.’s holdings in Evolus were worth $1,755,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Evolus by 2.0% in the first quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company’s stock worth $38,906,000 after buying an additional 62,664 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Evolus in the 2nd quarter valued at $22,431,000. Soleus Capital Management L.P. raised its stake in Evolus by 96.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after acquiring an additional 1,039,842 shares during the last quarter. Frontier Capital Management Co. LLC raised its stake in Evolus by 37.9% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company’s stock worth $15,333,000 after acquiring an additional 457,533 shares during the last quarter. Finally, Millennium Management LLC lifted its position in Evolus by 1.7% during the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock worth $16,746,000 after acquiring an additional 23,605 shares during the period. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Trading Down 5.3%

Shares of EOLS stock opened at $6.81 on Wednesday. The stock has a 50 day moving average of $6.89 and a 200 day moving average of $7.57. The stock has a market cap of $441.42 million, a P/E ratio of -7.40 and a beta of 0.87. Evolus, Inc. has a twelve month low of $5.71 and a twelve month high of $17.12.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.05. The business had revenue of $68.97 million for the quarter, compared to analyst estimates of $91.23 million. Evolus had a negative return on equity of 759.04% and a negative net margin of 20.49%. On average, research analysts predict that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on EOLS. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a report on Monday. Wall Street Zen upgraded Evolus from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Mizuho reduced their price target on shares of Evolus from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Monday, December 1st. Finally, BTIG Research restated a “buy” rating and set a $18.00 price objective on shares of Evolus in a research note on Monday, September 8th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $20.80.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.